Catabasis’ proprietary chemistry platform produces new chemical entities (NCEs) that are conjugates of two clinically proven entities. The company’s SMART linker technology provides an algorithm that enables Catabasis to move rapidly from concept to clinical candidate. This novel approach produces NCEs with superior efficacy and safety. The NCEs superior efficacy is due to targeting two opposing nodes in a disease pathway to produce a synergistic outcome. Superior safety is achieved by utilizing entities with proven clinical safety profiles and creating NCEs that are inactive until hydrolyzed in target tissues.
This unique approach provides the following:
- Enhanced efficacy. The proven effect of the two products acting synergistically on the targeted pathway amplifies the efficacy beyond the simple combination of the two products alone.
- Improved safety and tolerability. Products are chosen with known clinical and safety profiles. In addition, the conjugate is inactive until the SMART linker is cleaved intracellularly within the target cells.
- De-risked development path.The conjugates are created from known, clinically validated, safe and well tolerated products, minimizing the risk of safety or tolerability issues.
- Intellectual property. The entire platform, the linkers and all conjugates are protected under IP that is owned by the company.